• Western blot analysis of extracts of various cell lines, using LMO4 Rabbit monoclonal antibody (STJ11103605) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (STJS000856) at 1:10000 dilution. Lysates/proteins: 25 Mu g per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 180s.

Anti-LMO4 antibody (66-165) [S5MR] (STJ11103605)

SKU:
STJ11103605

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit monoclonal antibody anti-LMO4 (66-165) is suitable for use in Western Blot research applications.
Clonality: Monoclonal
Clone ID: S5MR
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.02% Sodium Azide, 0.05% BSA, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: WB 1:500-1:1000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: LMO4
Gene ID: 8543
Uniprot ID: LMO4_HUMAN
Immunogen Region: 66-165
Immunogen: A synthetic peptide corresponding to a sequence within amino acids 66-165 of human LMO4 (P61968).
Immunogen Sequence: TKSGMILCRNDYIRLFGNSG ACSACGQSIPASELVMRAQG NVYHLKCFTCSTCRNRLVPG DRFHYINGSLFCEHDRPTAL INGHLNSLQSNPLLPDQKVC
Function Transcription cofactor. Plays a role in establishing motor neuron identity, in concert with MNX1, acting, at least in part, to disrupt LDB1-LHX3 complexes thereby negatively modulating interneuron genes in motor neurons.
Protein Name Lim Domain Transcription Factor Lmo4
Breast Tumor Autoantigen
Lim Domain Only Protein 4
Lmo-4
Alternative Antibody Names Anti-Lim Domain Transcription Factor Lmo4 antibody
Anti-Breast Tumor Autoantigen antibody
Anti-Lim Domain Only Protein 4 antibody
Anti-Lmo-4 antibody
Anti-LMO4 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance